357 related articles for article (PubMed ID: 15225110)
1. Cilostazol: improving walking distance in patients with intermittent claudication.
Collinson DJ; Donnelly R
Expert Rev Cardiovasc Ther; 2004 Jul; 2(4):503-9. PubMed ID: 15225110
[TBL] [Abstract][Full Text] [Related]
2. Cilostazol: new drug. Intermittent claudication: too little efficacy, too many risks.
Prescrire Int; 2009 Apr; 18(100):56-9. PubMed ID: 19585717
[TBL] [Abstract][Full Text] [Related]
3. Differential effects of cilostazol and pentoxifylline on vascular endothelial growth factor in patients with intermittent claudication.
Lee TM; Su SF; Tsai CH; Lee YT; Wang SS
Clin Sci (Lond); 2001 Sep; 101(3):305-11. PubMed ID: 11524048
[TBL] [Abstract][Full Text] [Related]
4. Effect of cilostazol on treadmill walking, community-based walking ability, and health-related quality of life in patients with intermittent claudication due to peripheral arterial disease: meta-analysis of six randomized controlled trials.
Regensteiner JG; Ware JE; McCarthy WJ; Zhang P; Forbes WP; Heckman J; Hiatt WR
J Am Geriatr Soc; 2002 Dec; 50(12):1939-46. PubMed ID: 12473004
[TBL] [Abstract][Full Text] [Related]
5. Cilostazol: a review of its use in intermittent claudication.
Chapman TM; Goa KL
Am J Cardiovasc Drugs; 2003; 3(2):117-38. PubMed ID: 14727939
[TBL] [Abstract][Full Text] [Related]
6. New treatment options in intermittent claudication: the US experience.
Hiatt WR
Int J Clin Pract Suppl; 2001 Apr; (119):20-7. PubMed ID: 11355276
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of cilostazol, a novel phosphodiesterase inhibitor in patients with intermittent claudication.
Samra SS; Bajaj P; Vijayaraghavan KS; Potdar NP; Vyas D; Devani RG; Ballary C; Desai A
J Indian Med Assoc; 2003 Sep; 101(9):561-2, 564. PubMed ID: 15168999
[TBL] [Abstract][Full Text] [Related]
8. The role of cilostazol (Pletal) in the management of intermittent claudication.
Bradbury AW
Int J Clin Pract; 2003 Jun; 57(5):405-9. PubMed ID: 12846346
[TBL] [Abstract][Full Text] [Related]
9. Cilostazol: a novel treatment option in intermittent claudication.
Cariski AT
Int J Clin Pract Suppl; 2001 Apr; (119):11-8. PubMed ID: 11355274
[TBL] [Abstract][Full Text] [Related]
10. A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial.
Beebe HG; Dawson DL; Cutler BS; Herd JA; Strandness DE; Bortey EB; Forbes WP
Arch Intern Med; 1999 Sep; 159(17):2041-50. PubMed ID: 10510990
[TBL] [Abstract][Full Text] [Related]
11. Effect of cilostazol in patients with intermittent claudication: a randomized, double-blind, placebo-controlled study.
Strandness DE; Dalman RL; Panian S; Rendell MS; Comp PC; Zhang P; Forbes WP
Vasc Endovascular Surg; 2002; 36(2):83-91. PubMed ID: 11951094
[TBL] [Abstract][Full Text] [Related]
12. Evidence-based symptom relief of intermittent claudication: efficacy and safety of cilostazol.
Donnelly R
Diabetes Obes Metab; 2002 Mar; 4 Suppl 2():S20-5. PubMed ID: 12180354
[TBL] [Abstract][Full Text] [Related]
13. Cilostazol: treatment of intermittent claudication.
Reilly MP; Mohler ER
Ann Pharmacother; 2001 Jan; 35(1):48-56. PubMed ID: 11197586
[TBL] [Abstract][Full Text] [Related]
14. Effects of cilostazol on lipid and fatty acid metabolism.
Nakamura N; Osawa H; Yamabe H; Okumura K; Hamazaki T
Clin Exp Med; 2005 Mar; 4(4):170-3. PubMed ID: 15750763
[TBL] [Abstract][Full Text] [Related]
15. Long-term safety of cilostazol in patients with peripheral artery disease: the CASTLE study (Cilostazol: A Study in Long-term Effects).
Hiatt WR; Money SR; Brass EP
J Vasc Surg; 2008 Feb; 47(2):330-336. PubMed ID: 18155871
[TBL] [Abstract][Full Text] [Related]
16. L-Carnitine plus cilostazol versus cilostazol alone for the treatment of claudication in patients with peripheral artery disease: a multicenter, randomized, double-blind, placebo-controlled trial.
Goldenberg NA; Krantz MJ; Hiatt WR
Vasc Med; 2012 Jun; 17(3):145-54. PubMed ID: 22615190
[TBL] [Abstract][Full Text] [Related]
17. Meta-analysis of results from eight randomized, placebo-controlled trials on the effect of cilostazol on patients with intermittent claudication.
Thompson PD; Zimet R; Forbes WP; Zhang P
Am J Cardiol; 2002 Dec; 90(12):1314-9. PubMed ID: 12480040
[TBL] [Abstract][Full Text] [Related]
18. The novel phosphodiesterase inhibitor NM-702 improves claudication-limited exercise performance in patients with peripheral arterial disease.
Brass EP; Anthony R; Cobb FR; Koda I; Jiao J; Hiatt WR
J Am Coll Cardiol; 2006 Dec; 48(12):2539-45. PubMed ID: 17174195
[TBL] [Abstract][Full Text] [Related]
19. Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease.
Money SR; Herd JA; Isaacsohn JL; Davidson M; Cutler B; Heckman J; Forbes WP
J Vasc Surg; 1998 Feb; 27(2):267-74; discussion 274-5. PubMed ID: 9510281
[TBL] [Abstract][Full Text] [Related]
20. The role of cilostazol in the treatment of intermittent claudication.
Barnett AH; Bradbury AW; Brittenden J; Crichton B; Donnelly R; Homer-Vanniasinkam S; Mikhailidis DP; Stansby G
Curr Med Res Opin; 2004 Oct; 20(10):1661-70. PubMed ID: 15462700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
